Skip to Main Content

Author Details

Thorsten Schlomm
Charite - University Hospital Berlin
2004
327
57
PMIDPaper TitleJournal TitlePublished Year
36656126Automated Ki-67 labeling index assessment in prostate cancer using artificial intelligence and multiplex fluorescence immunohistochemistry.J Pathol2023
35717940Subjective Outcome after Discontinuation of Botulinum Toxin-A Detrusor Injection for Lower Urinary Tract Disorders: The Majority Suffers!Urol Int2023
34773679A non-inferiority comparative analysis of micro-ultrasonography and MRI-targeted biopsy in men at risk of prostate cancer.BJU Int2022
35659150Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study.Eur Urol2022
36353660Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer.Eur Urol Open Sci2022
35887247Prediction of Response to Cisplatin-Based Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer Patients by Molecular Subtyping including KRT and FGFR Target Gene Assessment.Int J Mol Sci2022
35948575Follow-up of men with a PI-RADS 4/5 lesion after negative MRI/Ultrasound fusion biopsy.Sci Rep2022
36152841GATA3 expression loss is linked to stage progression but is unrelated to prognosis in muscle-invasive urothelial carcinoma of the bladder.Hum Pathol2022
35160243Kidney Perfusion in Contrast-Enhanced Ultrasound (CEUS) Correlates with Renal Function in Living Kidney Donors.J Clin Med2022
35157098[Molecular diagnostics and molecular tumor board in uro-oncology : Precision medicine using the example of metastatic castration-resistant prostate cancer].Urologe A2022
34928524Nomograms including the UBC<sup>®</sup> Rapid test to detect primary bladder cancer based on a multicentre dataset.BJU Int2022
32654967Evolution of Targeted Prostate Biopsy by Adding Micro-Ultrasound to the Magnetic Resonance Imaging Pathway.Eur Urol Focus2021
33628598Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer.Cancer Biol Med2021
33491944Overexpression of the TRIM24 E3 Ubiquitin Ligase is Linked to Genetic Instability and Predicts Unfavorable Prognosis in Prostate Cancer.Appl Immunohistochem Mol Morphol2021
33608228Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy.Clin Genitourin Cancer2021
34884335Outcomes of Deceased Donor Kidney Transplantation in the Eurotransplant Senior Program with A Focus on Recipients â¿¥75 Years.J Clin Med2021
33315136[Network medicine and health services research in urology].Urologe A2021
33315135[Precision oncology : How can high-quality healthcare remain affordable for all in the face of diagnostic and therapeutic costs?]Urologe A2021
33475783[Innovations in urology: essential for progress].Urologe A2021
33045100Chromosome 5 harbors two independent deletion hotspots at 5q13 and 5q21 that characterize biologically different subsets of aggressive prostate cancer.Int J Cancer2021
31165229The gordian knots.World J Urol2020
31745645Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer.World J Urol2020
31893572Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients.Cancer Med2020
31687881High RSF1 protein expression is an independent prognostic feature in prostate cancer.Acta Oncol2020
31736271Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer.Mol Oncol2020
32094363Subcellular Compartmentalization of Survivin is Associated with Biological Aggressiveness and Prognosis in Prostate Cancer.Sci Rep2020
33339518Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer.BMC Cancer2020
33195694Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence.Biomed Res Int2020
33050010Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of <i>KRT5</i>, <i>KRT20</i>, and <i>ERBB2</i> in Muscle-Invasive Bladder Cancer Treated by Adjuvant Chemotherapy.Int J Mol Sci2020
33064171[Results of the CGC/TCGA Pan-Cancer Analysis of the Whole Genomes (PCAWG) Consortium].Urologe A2020
32776718High B7-H3 expression is linked to increased risk of prostate cancer progression.Pathol Int2020
32628300Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer.Prostate2020
32677026Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions.Pathol Oncol Res2020
32901137EGFR as a stable marker of prostate cancer dissemination to bones.Br J Cancer2020
32750503Xenograft-derived mRNA/miR and protein interaction networks of systemic dissemination in human prostate cancer.Eur J Cancer2020
32417965Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers.Virchows Arch2020
32150281Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers.Int J Cancer2020
32143573Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion.Mol Med2020
32545566Should We Perform Old-for-Old Kidney Transplantation during the COVID-19 Pandemic? The Risk for Post-Operative Intensive Stay.J Clin Med2020
32467601A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy.Br J Cancer2020
32466503Robot-Assisted versus Laparoscopic Donor Nephrectomy: A Comparison of 250 Cases.J Clin Med2020
32377272Upregulation of Phosphatase 1 Nuclear-Targeting Subunit (PNUTS) Is an Independent Predictor of Poor Prognosis in Prostate Cancer.Dis Markers2020
32323460Solid organ transplantation programs facing lack of empiric evidence in the COVID-19 pandemic: A By-proxy Society Recommendation Consensus approach.Am J Transplant2020
32488048Up regulation of the Hippo signalling effector YAP1 is linked to early biochemical recurrence in prostate cancers.Sci Rep2020
32295696Repeat Radiation for Local Recurrence of Head and Neck Tumors and in Prostate Cancer.Dtsch Arztebl Int2020
32317175High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer.Pathology2020
32314536Upregulation of PTTG1 is associated with poor prognosis in prostate cancer.Pathol Int2020
31243337Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy.Prostate Cancer Prostatic Dis2020
31601564Tumor-Associated Release of Prostatic Cells into the Blood after Transrectal Ultrasound-Guided Biopsy in Patients with Histologically Confirmed Prostate Cancer.Clin Chem2020
30430607Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.Prostate2019
  • 1 - 50 of 327

Recommended Authors

Simpa S Salami
University of Michigan Medical School ann arbor
Career Start Year 2012
Number of shared co-authors 11
Agnes Marije Hoogland
Erasmus Medical Center
Career Start Year 2011
Number of shared co-authors 7
Adam G Sowalsky
National Cancer Institute
Career Start Year 2010
Number of shared co-authors 8
Shancheng Ren
Shanghai Changzheng Hospital
Career Start Year 2007
Number of shared co-authors 13
Verena Sailer
Institute for Pathology, University Hospital Schleswig-Holstein
Career Start Year 2007
Number of shared co-authors 5
Alastair D Lamb
University of Oxford
Career Start Year 2007
Number of shared co-authors 25
Michael C Haffner
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 22
Anne Y Warren
Cambridge University Hospitals National Health Service Foundation Trust
Career Start Year 2003
Number of shared co-authors 23
Scott A Tomlins
Rogel Cancer Center, University of Michigan Medical School ann arbor
Career Start Year 2003
Number of shared co-authors 27
Christopher E Barbieri
Weill Cornell Medical College
Career Start Year 2003
Number of shared co-authors 15
Antonio Hurtado-Coll
University of British Columbia
Career Start Year 2002
Number of shared co-authors 15
Tarek A Bismar
University of Calgary Cumming School of Medicine, Rockyview General Hospital
Career Start Year 2002
Number of shared co-authors 19
Mathieu Latour
Centre Hospitalier de l'Universite de Montreal
Career Start Year 2001
Number of shared co-authors 9
Jiaoti Huang
Duke University School of Medicine
Career Start Year 2000
Number of shared co-authors 15
Hayley C Whitaker
University College London
Career Start Year 1999
Number of shared co-authors 19
Geert J L H van Leenders
Erasmus MC Cancer Institute, University Medical Center
Career Start Year 1998
Number of shared co-authors 16
Todd M Morgan
University of Michigan ann arbor
Career Start Year 1997
Number of shared co-authors 25
Inge M van Oort
Radboud University Medical Center
Career Start Year 1995
Number of shared co-authors 16
Lars Egevad
Karolinska Institute
Career Start Year 1995
Number of shared co-authors 20
Louis Lacombe
CHU de Quebec-Universite Laval
Career Start Year 1994
Number of shared co-authors 18
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Career Start Year 1993
Number of shared co-authors 32
Penny Flohr
The Institute of Cancer Research
Career Start Year 1993
Number of shared co-authors 18
Rosina T Lis
National Cancer Institute
Career Start Year 1992
Number of shared co-authors 13
Neil E Fleshner
University of Toronto
Career Start Year 1989
Number of shared co-authors 39
Armen Aprikian
McGill University Health Centre, McGill University
Career Start Year 1987
Number of shared co-authors 11
Alan W Partin
The Brady Urological Institute, Johns Hopkins University School of Medicine
Career Start Year 1987
Number of shared co-authors 24
Dominique Trudel
Institut du cancer de Montreal
Career Start Year 1985
Number of shared co-authors 18
Eric A Klein
Cleveland Clinic
Career Start Year 1984
Number of shared co-authors 34
Bruce J Trock
Johns Hopkins University School of Medicine
Career Start Year 1984
Number of shared co-authors 25
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Career Start Year 1981
Number of shared co-authors 28

Collaborators

Markus Graefen
University Hospital Frankfurt, Goethe University Frankfurt am Main
Co-authored papers 199
Guido Sauter
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Co-authored papers 175
Hartwig Huland
Martini-Klinik Prostate Cancer Center, University Hospital-Hamburg-Eppendorf
Co-authored papers 166
Ronald Simon
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Co-authored papers 144
Claudia Hube-Magg
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Co-authored papers 73
Martina Kluth
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Co-authored papers 73
Christina M??ller-Koop
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Co-authored papers 59
Holger S??ltmann
German Cancer Research Center (DKFZ)
Co-authored papers 18
Alberto Briganti
IRCCS San Raffaele Scientific Institute
Co-authored papers 17
Derya Tilki
Universitatsklinikum Hamburg-Eppendorf
Co-authored papers 15
Joachim Weischenfeldt
University of Copenhagen
Co-authored papers 13
Jan O Korbel
European Bioinformatics Institute (EMBL-EBI)
Co-authored papers 13
Christoph Plass
German Cancer Research Center
Co-authored papers 11
Jan Meiners
University Medical Center Hamburg-Eppendorf
Co-authored papers 9
Benedikt Brors
German Cancer Research Center (DKFZ)
Co-authored papers 7
Clarissa Gerh??user
German Cancer Research Center (DKFZ)
Co-authored papers 5
Stephen J Freedland
Cedars-Sinai Medical Center
Co-authored papers 5
Hartmut Schl??ter
University Medical Center Hamburg-Eppendorf
Co-authored papers 5
Ian G Mills
Queen's University Belfast
Co-authored papers 4
Roland Eils
Berlin Institute of Health (BIH) and Charite
Co-authored papers 4
Lars Feuerbach
German Cancer Research Center (DKFZ)
Co-authored papers 4
Olga Bogatyrova
German Cancer Research Center
Co-authored papers 3
Yassen Assenov
German Cancer Research Center (DKFZ)
Co-authored papers 3
Giorgio Gandaglia
IRCCS San Raffaele Scientific Institute, Italy Vita-Salute San Raffaele University
Co-authored papers 3
Fred Saad
University of Montreal Health Center
Co-authored papers 3
Robert G Bristow
University of Toronto
Co-authored papers 3
Marie-Laure Yaspo
Max Planck Institute for Molecular Genetics
Co-authored papers 3
Chris Lawerenz
German Cancer Research Center (DKFZ)
Co-authored papers 3
Vyacheslav Amstislavskiy
Max-Planck-Institute for Molecular Genetics
Co-authored papers 2
Arnulf Stenzl
Eberhard Karls University of Tubingen
Co-authored papers 2
Release 1.2